Svn53 67 M57 Klh Peptide

SurVaxM (SVN53-67/M57-KLH Peptide) is a peptide cancer vaccine developed by MimiVax LLC, a 2012 spin-out of Roswell Park broad Cancer Center. It teaches the immune system to recognize and kill tumor cells expressing survivin - a protein cancer cells use to dodge programmed cell death. The Phase 2 trial in the database (NCT02455557) tested SurVaxM plus standard-of-care temozolomide (the oral chemotherapy used in nearly all newly diagnosed glioblastoma) in patients with newly diagnosed glioblastoma, a brain cancer with median survival around 15 months on current treatment [1]. Final Phase 2a data were published in the Journal of Clinical Oncology (Ahluwalia et al. 2023) showing median PFS of 11.4 months and median OS of 25.9 months [2]. The asset has since moved into the randomized Phase 2b SURVIVE trial (NCT05163080), and represents one of the few cancer vaccines still alive in glioblastoma after a long history of failed immunotherapy trials in this disease.

Novel compound, never approved anywhere. The Roswell Park Phase 2a (NCT02455557) enrolled 63-66 patients (single-arm, primary endpoint PFS at 6 months) and is complete; final data published in JCO 2023 [1][2]. MimiVax has advanced SurVaxM into the SURVIVE randomized Phase 2b trial (NCT05163080) against placebo plus temozolomide in newly diagnosed GBM. SURVIVE is fully enrolled (target ~228-265 patients across 15 US sites, 3:2 randomization to SurVaxM vs. placebo, primary endpoint overall survival, interim analysis after 50% of deaths) and passed its first interim analysis in early 2025 with a recommendation to continue [3][4]. The vaccine is also being tested in metastatic neuroendocrine carcinomas (NCT06202066, Phase 2, n=60 recruiting), multiple myeloma maintenance (NCT02334865, Phase 1), and combined with pembrolizumab in recurrent GBM (NCT04013672, Phase 2, completed enrollment - no peer-reviewed results publicly reported as of May 2026) [5][6][7]. SurVaxM has received FDA Orphan Drug designation and Fast Track designation for newly diagnosed glioblastoma. The GBM franchise is the commercial center of gravity; neuroendocrine and myeloma are smaller exploratory shots from the same academic group.

Survivin (gene name BIRC5) is a protein that does two things cancer cells need: it blocks apoptosis (the cell's built-in self-destruct program) and it helps chromosomes split during cell division [8]. Healthy adult tissues barely express it. Tumors crank it out - including >80% of glioblastomas. That expression pattern makes survivin a clean tumor-associated antigen: hit it with an immune response and you mostly hurt cancer cells, not normal tissue. SurVaxM is a peptide containing the SVN56-64/M57 core epitope (with flanking residues 53-67) - methionine substituted for cysteine at position 57 makes it bind HLA class I more tightly, presenting it more efficiently to CD8+ killer T cells. The peptide is conjugated to keyhole limpet hemocyanin (KLH), a large immunogenic protein from sea snails that acts as the carrier signal telling the immune system 'this is foreign, pay attention.' Given with sargramostim (GM-CSF) to recruit dendritic cells. An important commercial-ceiling constraint: SurVaxM eligibility requires the patient to express HLA-A*02, A*03, A*11, or A*24 - covering most but not all of the population (Phase 2 enrollment required HLA typing and IHC-confirmed survivin expression) [9]. Phase 1 work in recurrent malignant glioma showed measurable survivin-specific T-cell and antibody responses in most treated patients [9]. The mechanism is biologically coherent. The harder question is whether peptide vaccines can generate enough sustained T-cell killing to matter clinically in immunologically 'cold' tumors (tumors with few immune cells infiltrating them, making immune-activating therapies harder to engage) like GBM.

NCT02455557 is a single-arm Phase 2a, n=63 evaluable, newly diagnosed glioblastoma patients who completed standard chemoradiation (the 'Stupp regimen' of radiation plus temozolomide - the standard chemotherapy backbone) without progression. SurVaxM is dosed during temozolomide maintenance. Primary endpoint: PFS at 6 months. Sponsor: Roswell Park Cancer Institute; MimiVax owns the asset [1]. Final published results (Ahluwalia et al., JCO 2023): 60 of 63 evaluable patients (95.2%) reached PFS-6, median PFS 11.4 months and median OS 25.9 months from first SurVaxM dose [2]. Historical benchmarks for newly diagnosed GBM on Stupp are ~6.9 months PFS and ~15 months OS. The design's main weakness is no concurrent control arm - efficacy reads against historical benchmarks, which is always a noisy comparison given selection bias for patients fit enough to enter a vaccine trial (those who survived chemoradiation without progression and met HLA + survivin-expression criteria). The properly powered question gets answered by the randomized SURVIVE Phase 2b (NCT05163080), which compares SurVaxM plus temozolomide against placebo plus temozolomide with overall survival as the primary endpoint [3][4]. SURVIVE is fully enrolled and passed its first interim analysis. That readout is the one that matters for a regulatory path.

The model gives this drug a 7% chance of eventually being approved. It starts from the historical rate for Phase 2 drugs in this area - about 13% - then adjusts based on ten facts about the trial and its sponsor. The estimate is helped by the trial's non-randomized design and its light or open-label blinding, and held back by the sponsor's thin approval record and weak earlier-phase results. The remaining facts fall close to average for this stage, leaving the estimate near where the base rate started it.

Efficacy risk dominates. The Phase 2a data is single-arm, and historical-control comparisons in GBM are unreliable - molecular subtypes heavily influence baseline survival, particularly MGMT methylation status (MGMT methylation is a tumor DNA repair marker that predicts better response to temozolomide; patients with methylated tumors live considerably longer regardless of added treatment), and trial populations skew toward better-prognosis patients. The SURVIVE Phase 2b OS readout is the real test. Class risk is substantial: cancer vaccines have failed in GBM repeatedly (rindopepimut/Rintega failed Phase 3 in ACT IV despite encouraging Phase 2 data), and the failure pattern is usually 'immune response confirmed, survival benefit not.' Note: DCVax-L (Northwest Biotherapeutics) submitted a Marketing Authorization Application to the UK MHRA in December 2023 under the rapid 150-day pathway; a decision has not been finalized as of this writing but, if approved, DCVax-L would become the first cancer vaccine authorized for GBM anywhere. Its survival benefit remains contested by statisticians due to the external control / crossover design of its Phase 3 trial, but the precedent matters for SurVaxM. GBM-specific risk: patients are often on dexamethasone for cerebral edema, which suppresses the exact T-cell response the vaccine is trying to generate. Population-ceiling risk: SurVaxM eligibility requires HLA-A*02, A*03, A*11, or A*24 expression plus IHC-confirmed survivin expression - that gates a meaningful share of the GBM population out of treatment. Safety profile has been clean across Phase 1/2 - peptide vaccines rarely produce serious on-target toxicity since survivin expression in normal adult tissue is minimal. Commercial risk: even if approved, newly diagnosed GBM is ~12,000 US cases/year, and the HLA filter cuts that further. Pricing power is real (high unmet need, orphan), but MimiVax has raised only ~$25M total (Buffalo Capital Partners, Varia Ventures, Fosun Pharma, Brain Tumor Investment Fund/NBTS, Sontag Foundation, MEDA Angels, Tech Coast Angels, Roswell Park) [11] - commercialization will almost certainly require a partnership or acquisition. MimiVax already has an exclusive China licensing deal with Fosun Pharma [11], which is a relevant precedent for similar OUS deals.

Worth watching, with one specific catalyst: the randomized Phase 2b SURVIVE OS readout in newly diagnosed GBM. That data tells you whether SurVaxM joins Sipuleucel-T as a working therapeutic cancer vaccine or joins rindopepimut and the rest of the GBM immunotherapy graveyard. The published Phase 2a data - 11.4-month median PFS, 25.9-month median OS against ~6.9/~15-month historical benchmarks - is encouraging enough that this isn't noise. The competitive frame has shifted: DCVax-L's pending UK MHRA decision (MAA submitted Dec 2023 under the 150-day rapid pathway) means the regulatory path for a GBM cancer vaccine could be open within ~12 months [12][13]. SurVaxM's off-the-shelf peptide format vs. DCVax-L's autologous dendritic-cell manufacturing is a real differentiator on cost of goods, scalability, and time-to-treatment - if both are competing for the same indication, that matters. The pembrolizumab combination data from NCT04013672 (Phase 2, completed enrollment) is also worth tracking - but no peer-reviewed publication or detailed conference report is publicly available as of May 2026, so treat it as a known unknown rather than a near-term catalyst [7]. MimiVax is private with ~$25M raised across a syndicate that includes Fosun Pharma (Chinese license partner), so there's no public market exposure to trade around this. Timing: SURVIVE is fully enrolled with primary OS analysis after a pre-specified event count. Based on the early-2025 first interim analysis and typical newly-diagnosed-GBM event-accrual rates, the primary readout is plausibly 2026-2027. Watch for: SURVIVE primary OS data; a partnership/acquisition tied to the readout; the MHRA's decision on DCVax-L (which will reset the regulatory landscape for the entire class).